Cosci MED-TECH Co., Ltd.

Main purpose 1: Using the anhydrous swallowable granules (15 mg) of ambroxol hydrochloride held by Shandong Kecheng Pharmaceutical Technology Co., Ltd. as the test drug and the ambroxol hydrochloride tablets (30 mg) (trade name: Surbronc®) produced by Sanofi-Aventis France as the control drug, the pharmacokinetic parameters of the test drug and the control drug in healthy subjects under fed and fasting conditions were investigated to evaluate the bioequivalence of the two preparations. . Main purpose 2: Evaluation of the mouthfeel of the anhydrous swallowable granules of the test drug. Secondary purpose: Observe the safety of the test drug and the control drug in healthy Chinese subjects.

Primary purpose: To compare the absorption rate and extent of azithromycin swallowable granules (0.1 g) produced by Harbin Kexin Bicheng Pharmaceutical Technology Development Co., Ltd. in healthy Chinese subjects, using azithromycin dry suspension (0.1 g) (trade name: Xishumei®) produced by Pfizer Pharmaceuticals Co., Ltd. as the control drug, and to evaluate the taste of the granules. Secondary purpose: To observe the safety of the test drug and the control drug in healthy Chinese subjects.

Primary objective: To compare the absorption rate and extent of ondansetron hydrochloride anhydrous swallowable granules (4 mg) held by Harbin Kexin Bicheng Pharmaceutical Technology Development Co., Ltd. with ondansetron hydrochloride tablets (4 mg) (trade name: Zofran®) produced by GlaxoSmithKline as the control drug in healthy Chinese subjects, and to evaluate the taste of the anhydrous swallowable granules. Secondary objective: To observe the safety of the test drug and the control drug in healthy Chinese subjects.